Mariam Hassan

Dr. Mariam Hassan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Egyptian Journal of Medical Microbiology
Verified
Journal Article
Closed access
PDF file
MHMariam Hassan
Mariam Hassan
Background: There is a debate over the efficacy of corticosteroids (CS) in management of Coronavirus diseases 2019 (COVID-19); yet, few are declared about its role in treatment of mild conditions. Objectives: in this study, we aimed at investigating the role of corticosteroids in mild cases of COVID-19. Methodology: in a case control study, we included 100 patients with mild COVID-19. The incidence of improvement, disappearance of symptoms, appearance of new symptoms and deterioration were compared between cases and control group. Results: More than three fourths of the study participants showed improvement of symptoms, with disappearance of symptoms in 64% and 85% of group 1 and group 2, respectively. Only few numbers of patients deteriorated. Noticeably, a remarkable number of patients expressed new symptoms by the end of the study. Conclusions: corticosteroids has no role in clinical progression of cases with mild COVID-19. CS use should be reserved for severe symptoms of COVID-19.

8 March 2023 in Microbes and Infectious Diseases
Verified
Journal Article
Closed access
NMNageh Mahrous
Nageh Mahrous
ENEman Fahmy Nasrelden
Eman Fahmy Nasrelden
MHMariam Hassan
Mariam Hassan
MAMohamed Aboelmagd
Mohamed Aboelmagd
Background: treatment of Helicobacter pylori became mandatory for prevention and cure of most of upper gastrointestinal complaints. Despite the varieties in available therapeutic options, achieving a high eradication rate is very challenging. Currently, vonoprazan based protocols are being introduced, and they provide promising outcomes. We aimed at studying vonoprazan efficacy and safety for cure of Helicobacter pylori for Egyptian patients.Methods: in a prospective cohort study, we included 300 patients who tested positive for Helicobacter pylori to receive vonoprazan-based triple therapy for two weeks. Then, we assessed the cure rate, improvement of symptoms and side effects. Results: we found that vonoprazan-based triple therapy achieved an cure rate of 90%. There was a remarkable improvement in all presenting symptoms after complete cure with this regimen. Few adverse effects were observed not exceeding 9.3% of patients. Most common side effects were nausea (4.3%), burping (2.6%) and bloating (1.3%).Conclusions: vonoprazan-based triple therapy is effective and safe for cure of Helicobacter pylori.